Financials in USD. Standardized financial statements.
A compact view of how GreenLight Biosciences Holdings turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Revenue? | $6.38M | $0 | $962,000 | $3.00M |
| Revenue Growth? | 0.0% | -100.0% | -67.9% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 |
| Gross Profit? | $6.38M | $0 | $962,000 | $3.00M |
| Gross Margin? | +100.0% | 0.0% | +100.0% | +100.0% |
| Operating Expenses? | $169.34M | $108.56M | $53.25M | $32.20M |
| Operating Income? | -$163.92M | -$108.56M | -$52.28M | -$29.20M |
| EBITDA? | -$153.99M | -$102.75M | -$50.45M | -$27.65M |
| Income Before Tax | -$165.96M | -$112.31M | -$53.25M | -$28.65M |
| Income Tax Expense | $1.09M | $2.42M | $1.03M | $317,000 |
| Net Income? | -$167.06M | -$114.73M | -$54.28M | -$28.97M |
| EPS? | $-1.27 | $-0.93 | $-0.56 | $-0.30 |
| Diluted EPS? | $-1.27 | $-0.93 | $-0.56 | $-0.30 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality